Allurar CBL-514 Lipolysis: Binciken Mataki na 2
CBL‑514 wani allura ne da ake bincike don haifar da apoptosis na sel ɗin kitse (adipocytes) a cikin ciki. A gwajin mataki na 2 da aka gudanar a 2025 tare da mahalarta 76 da aka raba ta bazuwar, an samu raguwar ƙimar kitse da aka auna ta ultrasound idan aka kwatanta da saline, yayin da matsakaicin nauyin jiki ya tsaya ba tare da canji ba. Ƙididdigar ta gabatar da ƙirar gwajin, ƙimar 2 mg/cm², cikakkun bayanan tasiri da ƙananan lambobi, da hanyar DYRK1b/caspase da kamfanin ya ba da rahoto. An kuma bayyana iyakokin: ƙirar single‑blind, haɗin gwiwar mai tallafa, kusan 49 % rashin kammalawa, gajeren lokaci na bibiyar, da yawan samfurin mata.
Matsakaicin Magani na CBL‑514 – Menene Kimiyyar Sa?
Gwaje‑gwajen CBL‑514 su ne gwaje‑gwajen allura da ke binciken tasirin wannan magani, inda adadin 600 mg ke nufin iyakar adadin da ake amfani da shi a kowanne magani a gwaji, ba adadin da za a ci ba. Wannan makala ta bi takaitaccen binciken Phase 2a don tantance ƙimomi (1.2, 1.6, 2.0 mg/cm² a kan 150 cm², n=43, buɗe‑label) kuma ta fayyace asalin adadin 24.96 % da aka ambata. Sannan ta duba Phase 2 da aka gudanar da placebo, inda aka ci gaba da ƙimar 2.0 mg/cm² amma an ninka yanki zuwa 300 cm² tare da iyaka ta 600 mg. Za ku ga dalilin da yasa adadin mg ba za a iya kwatanta su tsakanin gwaje‑gwajen ba, abin da aka rubuta game da tsaro, da kuma dalilin da ya sanya har yanzu ba a amince da shi ba ko ba da shawara ba.
Shin CBL‑514 na ƙona mai ainihi? Ga abin da muka sani
Binciken mataki na biyu da aka gudanar a 2025 kan CBL‑514 bai nufin rage nauyin jiki ba; an duba ko alluran da aka yi a ƙirji za su iya rage aƙalla mililita 150 na kitse a ƙarƙashin fata ta hanyar ultrasound. Bayan makonni 8, kashi 69.6 % (16/23) na masu karɓar CBL‑514 sun cimma wannan ragi, yayin da babu ɗaya a rukunin placebo. Duk da haka, matsakaicin nauyin jiki bai ragu ba (ƙara 0.02 kg) kuma kusan rabi na mahalarta ba su kammala binciken ba. Martani a wurin allura ya kasance gama‑gari, ciki har da ƙura a fata a 71.4 % da zafi mai tsanani a 18.4 %. Wannan shine abin da binciken ya nuna da abin da bai nuna ba.
Ta yaya CBL‑514 ke aiki? Ilimin kimiyya
CBL‑514 ba a nuna shi a matsayin maganin narkewar ko kona kitse ba. Da'awar da ake yi ita ce yana hanawa kinase DYRK1b aiki sannan ya tilastawa ƙwayoyin kitse shiga apoptosis ta hanyar caspase‑3 da Bax/Bcl‑2. Hujjar wannan zaɓi ta samo asali ne daga rahotannin kamfanin da ba a wallafa ba a takardun Phase 2a da Phase 2, kuma ba a fayyace takamaiman tsarin sinadarin ba. Gwajin Phase 2 na 2025 ya auna girman kitse da ultrasound, hotuna, da aminci, ba tare da ƙarin bayanai kamar biopsi ko caspase ba. Wannan labarin na nuni da bambanci tsakanin tunanin sel da abin da aka auna a ɗan adam, ciki har da yawan mutuwar mahalarta da tsarin single‑blind.
Allurar rage kitsen CBL‑514: Menene kimiyya ke cewa?
CBL‑514 ta wuce gwajin mataki na biyu da aka sarrafa placebo a mujallar *Aesthetic Surgery Journal*, inda marubuta suka ce ta cika manyan manufofin da aka saita. Sai dai wannan bitar na nuna dalilan da ya sa dole a duba ƙirar gwajin sosai: an yi amfani da blind guda ɗaya, masu bincike da mai tallafa ba su da ɓoye, kuma mai tallafa ya shiga ƙirƙira, tantancewa da rubuta sakamakon. Daga cikin mahalarta 75 da aka ba da magani, kawai 38 suka kammala, kuma ƙungiyar da aka yi nazari a kai ta ƙunshi mutane 30 kacal. An dakatar da bibiyar bayan makonni 8, kuma samfurin ya fi yawa mata da fararen fata. Wannan labarin zai fayyace abin da gwajin zai iya tabbatarwa, abin da ba zai iya ba, da dalilin da ya sa ba za a ɗauke shi a matsayin shawara ta likita ko hujja da aka amince da ita ba.